Physician profile
Phyo Kyaw
NPI 1316333248
$3,395.20
in general payments reported to CMS, 2019-2025
15 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $90.67 · 2021: $144 · 2022: $194 · 2023: $1,085 · 2024: $228 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,900 · Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,899.80 |
| Food and Beverage | $807.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,314.10 | 2025 | Illumisite |
| Olympus Corporation of The Americas | $762.30 | 2023 | Single Use Suction Valve (Sterile) |
| Astrazeneca Pharmaceuticals LP | $344.86 | 2019-2023 | Breztri, Tezspire |
| Glaxosmithkline, LLC. | $192.19 | 2021-2025 | Nucala |
| Genentech USA, INC. | $190.66 | 2019-2020 | |
| United Therapeutics Corporation | $147.82 | 2024 | Tyvaso |
| Mylan Specialty L.P. | $141.59 | 2019-2022 | |
| Ethicon INC. | $118.72 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.46 | 2021-2023 | Ofev |
| Abbvie INC. | $34.03 | 2021-2025 | |
| Genzyme Corporation | $23.61 | 2021 | |
| Amgen INC. | $19.77 | 2024 | Tezspire |
| Grifols USA, LLC | $16.45 | 2023 | Prolastin-C Liquid |
| Nabriva Therapeutics, Plc | $14.70 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $13.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyo Kyaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.